Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adobe

Taiwan Semiconductor Manufacturing

The current five trillion-dollar companies listed on U.S. stock exchanges include Apple (NASDAQ: AAPL ), Microsoft (NASDAQ: MSFT ), Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ), Amazon (NASDAQ: AMZN ), and Nvidia (NASD AQ: NVDA ).  These five and two others, Meta Platforms (NASDAQ: META ) and Tesla (NASDAQ: TSLA ), make up “the Magnificent Seven”.

Meet the Next Trillion-Dollar Companies: Our Top 3 Picks

Abbott Labs

Archer-Daniels-Midland Company

Automatic Data Processing

Aflac

Albemarle

Amcor Plc

A. O. Smith

Air Products and Chemicals

Atmos Energy

Becton, Dickinson and Co.

Franklin Resources

Brown & Brown

Cardinal Health

Caterpillar

Chubb

Cincinnati Financial

Colgate-Palmolive

Clorox

Cintas Corp

Chevron

Dover

Ecolab

Con Ed

Emerson Electric

Essex Property Trust

Expeditors International of Washington

Federal Realty Investment Trust

General Dynamics

Genuine Parts

W.W. Grainger

Hormel Foods

Illinois Tool Works

Johnson & Johnson

Kimberly-Clark

Coca-Cola

New Linde PLC

Lowe's

McDonald's

Medtronic

McCormick

Nordson

NextEra Energy

Nucor

Realty Income Corp

PepsiCo

Procter & Gamble

Pentair

PPG Industries

Roper Technologies

Sherwin-Williams

S&P Global

Stanley Black & Decker

Sysco

Target

T. Rowe Price Group

V.F.

Walgreens

Walmart

West Pharmaceutical Services

Exxon Mobil

The highest yield isn't everything when it comes to finding the best dividend stocks. Income investors know there's no substitute for regular dividend increases over the long haul.

67 Best Dividend Stocks for Dependable Dividend Growth

DividendChannel.com has a list of 25 SAFE dividend stocks.  By the site's definition, these stocks have a reasonably high yield; the quarterly dividend is accelerating, they've never missed or lowered dividends and they have paid dividends for at least 20 years.

3 Dividend Stocks That Are Investor Safe Havens

Home Depot

Microsoft

AbbVie, Home Depot, and Microsoft are all solid dividend growth stocks. All of them should continue increasing their payouts for years to come.

3 Dividend Stocks That Can Power Your Portfolio for Decades

Often when income investors look for defensive companies paying big dividends, they are drawn to the Dividend Aristocrats.

7 High-Yielding Dividend Aristocrats Like AbbVie Are the Best Contrarian Ideas Now

CELEBRATING THE FIFTH ANNUAL BOTOX ® COSMETIC DAY, NEW AND LOYAL ALLĒ MEMBERS BENEFIT FROM MORE EXCITING OFFERS IRVINE, Calif. , Nov. 1, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating the fifth annual BOTOX® Cosmetic Day on Wednesday, November 15.

BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never Before

Analog Devices

Applied Materials

Advanced Micro Devices

AMETEK

ANSYS

Broadcom

Bath and Body Works

CVS Health

ON Semiconductor

Tired of the S&P 500's three-month losing streak? Help might be on the way in November.

November Is The S&P 500's Best Month — 10 Stocks Rally Every Time

Amgen

Bristol-Myers

Eli Lilly

Merck

The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector performance.

Investor patience tested as pharmaceutical stocks take a tumble

News for AbbVie Stock (ABBV)